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Original article 
Repeated lipopolysaccharide exposure modifies 
immune and sickness behaviour response in an 
animal model of chronic inflammation 
Abstract 
Repeated lipopolysaccharide (LPS) exposure is often used in longitudinal preclinical 
models of depression. However, the potential phenotypic differences from acute 
depression-mimicking effects are rarely described. This study compared chronic LPS 
administration of doses previously used in depression research to a new mode of 
escalating dose injections. Adult male BALB/c mice (n=8/group) were injected 
intraperitoneally with either a single 0.83 mg/kg dose, a repeated 0.1 mg/kg LPS dose or 
a dose which escalated weekly from 0.33 to 0.83 mg/kg LPS for six weeks. The escalating 
LPS group demonstrated most features of sickness behaviour such as weight loss and 
reduction in food intake every week, whist this effect was not sustained in other groups. 
Moreover, only in the escalating LPS group did most peripheral plasma cytokines levels, 
measured using Luminex® multiplex technology, such as interleukin 6 (IL-6), tumor 
necrosis factor α and IL-2 remain over 3 fold elevated on the 6th week. In addition, 
exposure to escalating doses led to a reduction of neuroblast maturation in the dentate 
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gyrus relevant for depression neurobiology. Therefore, this mode of injections might be 
useful in the studies attempting to replicate neurobiological aspects of the chronic 
inflammatory state observed in mood disorders. 
Keywords 
Lipopolysaccharide, chronic inflammation, sickness behaviour, adult neurogenesis, 
hippocampus, cytokine, microglia 
Introduction 
Acute administration of LPS, a proinflammatory agent derived from Gram-negative 
bacteria, induces a complex of behavioural reactions known as sickness behaviour (Kent 
et al., 1992). The parallel between sickness behaviour and symptoms of depression 
initially drawn by Smith (1991), as well as growing interest in inflammatory aspects of 
depression neurobiology encouraged the use of LPS as a model of the disorder. Yet the 
replication of the chronic nature of depression symptoms and neurobiology using LPS 
has proved to be a challenging task to date. 
The analogy between sickness behaviour and depressive symptoms has its limitations, 
as some responses such as hyperthermia are absent in depressed patients, while other 
parameters could change on a much wider spectrum (Dunn et al., 2005). For example, 
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appetite might be increased or decreased in patients, but only its loss is linked to LPS 
response; sickness behaviour is associated with hypersomnia, but depressed patients 
can present with either insomnia or hypersomnia (Otte et al., 2016).  However it has 
been subsequently shown that LPS exposure via i.p. injections also induces depression-
like behaviour in specific behavioural tests, such as increased immobility in the forced 
swim test (Godbout et al., 2007; O’Connor et al., 2009) and anhedonia in the sucrose 
consumption test and test of sexual behaviour (Painsipp et al., 2011; Yirmiya, 1996).  
While the construct validity of LPS-based models could be disputed due to pathogen-
induced rather than stress-related nature of symptoms, its main advantage consists of 
the similarity between its biological effects and neurobiological changes seen in 
depression. Firstly, pro-inflammatory cytokines elevated following LPS administration 
have also been found to be increased in depressed patients (for meta-analysis see Liu et 
al., 2012). Secondly, LPS has also been shown to induce hypercortisolism observed in 
some patient groups (Chen et al., 2005). Next, LPS exposure has been shown to decrease 
the level of adult hippocampal neurogenesis (AHN) implicated in the neurobiology of 
mood disorders (Samuels and Hen, 2011). Lastly, systemic LPS exposure is capable of 
inducing microglial activation in the brain (Buttini et al., 1996; Qin et al., 2007), similar 
to that demonstrated by clinical neuroimaging studies detecting increased microglial 
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activation marker translocator protein (TSPO) in depressed patients (Husain et al., 2015; 
Setiawan et al., 2015).  
However two major discrepancies exist between most LPS models and the course of the 
depressive disorder. Firstly, many studies using high doses of LPS (3-5mg/kg) have 
resulted in a drastic elevation in proinflammatory cytokines, as might be seen in sepsis 
(Anderson et al., 2016; Erickson and Banks, 2011).  Such changes might not be relevant 
for the subtler increases seen in depressed patients. Secondly, most behavioural and 
neurobiological effects of LPS are short-lived (24 hours or less) and therefore do not 
reflect the chronic nature of the disease (Godbout et al., 2007; Graciarena et al., 2013). 
To prolong the effects of LPS, some studies have employed protocols involving repeated 
LPS injections administered at various time intervals (Elgarf et al., 2014; Kubera et al., 
2013). Whilst such protocols induced more long-lasting phenotypes, they also resulted 
in a suppressed reaction of the immune system, known as LPS tolerance. For example, 
Kubera et al. (2013) showed that repeated administration of LPS (0.075-1.25mg/kg) led 
to a decreased sucrose preference in affected female mice, but also suppressed 
splenocyte proliferation and proinflammatory cytokine release in response to an acute 
immune challenge. In Elgarf et al.’s (2014) study, hippocampal TNFα used as a marker of 
brain inflammation was increased only after two but not six weeks of repeated 
0.05mg/kg LPS injections, a time point when the rats displayed social interaction deficits. 
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Thus, the effect of repeated administration may not simply produce a longitudinal 
version of the phenotype as induced by acute exposure. The difference in behavioural 
and neurobiological responses to acute versus repeated LPS injections has not been 
previously described in great detail. 
Therefore, the main aim of the current study was to investigate the effect of repeated 
administration of LPS within the dose range commonly used in depression studies on 
sickness behaviour response and neurobiological processes relevant for depression in 
comparison with the acute exposure. For this two modes of repeated LPS injections 
were compared to a single injection of 0.83mg/kg LPS (single LPS group), a dose which 
has been previously shown to induce a long-lasting phenotype (Painsipp et al., 2011). To 
avoid the development of LPS tolerance in repeated injections groups, several measures 
were taken: a weekly interval between injections was included to allow for immune 
system recovery; a relatively low dose (0.1 mg/kg) of LPS already utilised in depression 
models was used in 0.1 LPS group (Wang et al., 2011); a weekly increment from initial 
0.33 mg/kg to a final 0.83 mg/kg dose was used in the escalating LPS (0.33-0.83) group 
as dose increase has been shown to avoid habituation of immune response (Wickens et 
al., 2014). Sickness behaviour, plasma cytokine profile, and the state of adult 
hippocampal neurogenesis and microglial activation in the hippocampus were assessed 
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weekly or at the end of six weekly injections in each group, and compared to a control 
group injected with saline.  
Methods 
Animals 
Eight-week old male BALB/cAnNCrl mice were obtained from Charles River (Margate, 
Kent, U.K.). All animals were housed in the Biological Services Unit (BSU) at the Institute 
of Psychiatry, Psychology & Neuroscience in standard conditions (19-22°C, humidity 
55%, 12h:12h light:dark cycle with lights on at 7.30am, food [Rat and Mouse No. 1 Diet; 
Special Diet Services, Essex, UK] and water ad libitum). All procedures described in this 
paper were conducted on a single set of 34 mice (n=8 per LPS treated groups, n=10 in 
control group). In this set, mice were pair-housed with their litter mates in large cages 
45x28x13cm with environmental enrichment (small plastic and cardboard houses, 
cardboard tube, paper sizzle nest material; Datesand Ltd, Manchester, UK). All housing 
and experimental procedures were carried out in compliance with the local ethical 
review panel of King’s College London under a U.K. Home Office project licence held in 
accordance with the Animals (Scientific Procedures) Act 1986 and the European 
Directive 2010/63/EU. 
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LPS injections 
Sibling pairs were randomly assigned to one of four treatment groups, which received 
the following i.p. injections once a week (on Tuesdays at 10am) for six weeks:  (i) control 
group (SAL; n=10) received 100 µL of 0.9% saline each week; (ii) 0.1 LPS group (n=8) 
received 0.1mg/kg of LPS each week;  (iii) escalating LPS (0.33-0.83) group (n=8) received 
0.33 mg/kg of LPS on weeks one and two, 0.53 mg/kg of LPS on week three, 0.63 mg/kg 
on week four, 0.73 mg/kg on week five, 0.83 mg/kg on week six; (iv) single LPS group 
(n=8) received 0.83 mg/kg on week one, and 100 µL saline on weeks 2-6. For all 
injections LPS from E.Coli Serotype O127:B8 (L3129, Sigma Aldrich, Poole, UK) was used. 
LPS powder was freshly dissolved prior to injections in sterile saline (Aquapharm, Argyll, 
UK). Body and food weight were measured immediately before and 24 hours after saline 
or LPS administration, and the difference between the two data points was used as 
weight gain or food intake measures respectively. For depiction of the experimental 
design see Figure 1.  
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Figure 1 Experimental design. 
8 week old male BALB/cAnNCrl mice were injected with LPS (n=8/group) or saline (n=10/group) i.p. once a week for 6 
weeks. Experimental conditions included: 0.1 LPS group injected with 0.1 mg/kg LPS once weekly; Escalating LPS group 
injected with 0.33mg/kg on weeks 1 and 2, 0.53mg/kg on week 3, 0.63 mg/kg on week 4, 0.73 mg/kg on week 5 and 
0.83 mg/kg on week 6; Single LPS group injected with 0.83 mg/kg on week 1 and saline on weeks 2-6; SAL group was 
injected weekly with 0.9% saline solution. Blood was collected 2 hours after LPS injections on weeks 1 and 6; 
locomotion was measured 6 hours after LPS injections on weeks 1 and 6; weight change and food intake were 
measured during a 24-hour period after the LPS injections.  
Open field test 
The open field test was performed 6 hours after LPS injections on weeks one and six 
(between 4pm and 6pm). For this a dimly lit (20 Lux) circular arena measuring 40 cm in 
diameter was used. Each animal was placed in the arena facing the outer wall, and 
behaviour was video recorded for five minutes. The total distance travelled in the non-
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threatening outer zone was measured using the automated tracking system (Ethovision, 
Noldus Information Technologies, Wageningen, The Netherlands)  as described 
previously (Keers et al., 2012). 
Blood collection 
Blood was collected by incision method from the lateral tail vein (Sadler and Bailey, 
2013) 2 hours after either LPS or saline injections on weeks one and six. Whole blood 
(30-50µL) was collected into EDTA microvette CB 300 tubes (Sarstedt, Leicester, UK) and 
separated by centrifugation for 10min at 3000 rpm (4oC), after which plasma was 
manually transferred into a new sterile tube (1.5ml ‘Crystal clear’ microcentrifuge tube 
sterile, Starlab UK Ltd) and stored at -80°C. Another blood collection by method of 
cardiac puncture occurred after the terminal general anaesthesia had been induced by 
the injection of 40mg/kg of pentobarbital sodium i.p. (Euthatal, Merial Animal Health 
Ltd, Harlow, UK). 100-200μL of whole blood was collected using syringe injected into the 
cardiac cavity and subsequently processed as described above to measure 
corticosterone levels. 
Cytokine analysis 
The level of cytokines in the plasma was determined using the multiplex screening assay 
based on magnetic Luminex® xMAP® technology as described in Hye et al. (2014). For 
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this assay a custom-made pre-mixed multianalyte kit was purchased from RnD systems, 
Minneapolis, USA (catalogue N LXSAMSM). This kit contained multi-coloured magnetic 
microparticles pre-coated with antibodies to 8 selected analytes (granulocyte-monocyte 
colony stimulating factor (GM-CSF), interleukins IL-1β, IL-2, IL-6, IL-10, tumour necrosis 
factor alpha (TNFα), interferon gamma (IFNγ) and C-reactive protein (CRP)). To measure 
the fluorescent signal the Luminex® 100/200TM system based on xMAP® technology was 
used. Plasma samples were diluted 1:2 in calibration buffer, and all assay steps were 
conducted according to the manufacturer’s instructions. Due to small sample sizes, 
technical replicates for plasma samples were not included. Intraassay variability based 
on duplicates of the standard dilutions was estimated at 2.15 %CV. Interassay variability 
was not calculated as all samples were analysed on a single plate. Obtained data were 
analysed using five parameter logistic curve analysis using the My Assays online data 
tool, MyAssays Ltd., http://www.myassays.com/five-parameter-logistic-curve.assay . 
Immunohistochemistry 
For brain tissue collection, mice were anesthetised with 40mg/kg of pentobarbital 
sodium i.p. (Euthatal, Merial Animal Health Ltd, Harlow, UK) seven days after the last 
LPS or saline injections. Animals were subsequently transcardially perfused with saline 
and 4% paraformaldehyde (Paraformaldehyde, prills, 95%, 441244, Sigma-Aldrich, 
Poole, UK) in phosphate-buffered saline (pH = 7.4 from PBS tablets, 18912-014, Gibco 
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by Life Technologies, Paisley, UK) through the left cardiac ventricle. Brains were post-
fixed overnight in 4% PFA at 4°C, and subsequently stored at 4°C in 30% sucrose (Sigma-
Aldrich, Poole, UK) in PBS.  
Brain tissue was cut on a HM430 sliding microtome (Thermo Scientific) into serial 40µm 
thick coronal sections and stored in tris-buffered saline (TBS, pH=7.4) with 30% v/v 
glycerol, 15% w/v sucrose and 0.05% w/v sodium azide (all Sigma Aldrich, UK) to prevent 
bacterial growth and for cryoprotection at 4°C. For immunohistochemistry on free 
floating sections, every 6th section was washed in PBS 3x5min, incubated in 1% hydrogen 
peroxide (Sigma Aldrich, UK) for 30 mins with subsequent washing in PBS. Non-specific 
antibody binding was blocked by incubating sections in 10% NGS (Normal goat serum, 
S1000, Vector laboratories, UK)  in PBST (PBS with 0.25% TritonX (Sigma Aldrich, UK) for 
1hr. Sections were incubated in primary antibodies  (anti- doublecortin (DCX) diluted 
1:1000, ab18723, Abcam; Anti-ionized calcium-binding adapter molecule 1 (Iba1) 
diluted 1:500, 019-19741, Wako; anti CD68 diluted 1:2000, MCA 1957, ABD Serotec, 
Anti-Ki67 diluted 1:200, ab15580, Abcam; all made in rabbit) diluted in PBST with 10% 
NGS at 4°C, agitated on orbital shaker overnight. The next day sections were washed in 
PBS 3x5min and incubated in secondary antibody, biotinylated anti-Rabbit IgG made in 
goat (BA1000, Vector Laboratories, UK) for 2 hours at room temperature on an orbital 
shaker. Subsequently, sections were incubated in a solution containing avidin-biotin 
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complex (Vectastain Elite ABC Kit, PK6100, Vector Laboratories, UK) for signal 
amplification. The staining was visualised with diaminobenzidine (DAB, Sigma Aldrich, 
UK). Sections were rinsed PBS 3x5min, mounted on Superfrost Plus microscope slides 
(Thermo Scientific), air-dried, dehydrated in serial ethanol dilutions, cleared in xylene 
(Sigma Aldrich, UK) and coverslipped using Distyrene Plasticizer Xylene (DPX) (Sigma-
Aldrich, UK).  
Stereological analysis 
Stereological method was used to quantify the density of immunopositive cells as 
described previously (Thuret et al., 2009). An Axioskop 2 MOT Zeiss microscope and a 
semiautomatic stereology system (StereoInvestigator, Microbrightfield Inc.) were used 
to estimate the volume of the region of interest (ROI) and the total number of 
immunopositive cells in the ROI. For this estimation, the optical fractionator method in 
the StereoInvestigator software was used. The optical fractionator estimates the total 
volume of the ROI using the sectional ROI volume manually traced at x2.5 magnification 
and known intersection intervals (240µm). To estimate the number of positive cells, the 
software extrapolates the number of manually counted cells in the areas of chosen size 
(50μm x 50μm counting frames placed over grid with chosen size of X: 94.59μm and Y: 
182.53μm) of the ROI selected by systemic random sampling to the sectional volume of 
the region of interest. A chosen set number of average sampling sites per section was 
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50, while for each brain, 11 sections between stereotactic coordinates -1.06mm and -
3.80 relative to bregma (Franklin and Paxinos, 2012) were included into the optical 
fractionator analysis.  The density of Iba1 and DCX positive cells was calculated by 
dividing the estimated cell number by the estimated volume of the ROI.  
Classification of DCX positive cells by dendritic morphology 
The DCX positive cells were visually classified according to the categorization of Plumpe 
and co-workers (Plümpe et al., 2006). The AB group included cells with no or short plump 
processes, the CD group included cells with medium length processes without 
branching, and the EF group comprised cells with long branching dendrite(s) reaching 
the molecular layer. The density of each type of cells was determined using stereology 
as described in the previous section. 
Quantification of CD68 surface area 
For quantification of CD68 staining, digital images were taken using Zeiss Axioimager 
microscope and Zeiss AxioCam MR Rev3 camera at 40X magnification. Per each brain 
area (CA1, CA3, DG) identified using the Allen Mouse Brain reference coronal atlas, 1 
image was taken from every 2nd section between stereotactic coordinates -1.06mm and 
-3.80 relative to bregma (Franklin and Paxinos, 2012) to achieve equal intersection 
intervals (80µm). ImageJ software (Schneider et al., 2012) and macros code were kindly 
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provided by Lianne Hoeijmakers and Dr Aniko Korosi (Center for Neuroscience, 
Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, the 
Netherlands) were used to quantify the % surface area immunopositive for CD68.  
Statistical analysis 
A repeated measures two-way ANOVA was used to compare mean differences in weight 
gain, food intake and cytokine levels among treatment groups over the six weeks of 
injections. A one-way ANOVA was used to compare mean differences in DCX and Iba1 
hippocampal cell density among treatment groups. The Bonferroni correction for 
multiple comparisons (SAL vs 0.1/Escalating/Single LPS) was applied to post-hoc 
analyses to determine individual differences between treatment groups and the control 
group.  
Results 
Repeated LPS injections induced sickness behaviour each week for six weeks  
Body weight change and food intake were measured 24 hours after LPS injections to 
assess the suppressant effects of the sickness behaviour response on feeding (Biesmans 
et al., 2013).  Both the dose and chronicity of LPS affected weight gain and food intake 
(see Figure 2 and Table 1). On week one, LPS treated animals showed significantly 
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reduced body weight gain and/or reduced food intake compared to the saline control 
group, with the magnitude of effect dependant on the dose of LPS injected (see Figure 
2). On week two, only the 0.1 LPS group had a significant reduction in body weight gain. 
There were no significant differences in body weight gain in any of the LPS groups at 
week three, but from weeks four through six, there was a significant reduction in body 
weight gain in the group receiving escalating doses (0.33mg/kg-0.83mg/kg) of LPS 
compared to control.  The effect of LPS on food intake remained significant each 
subsequent week for the escalating LPS (0.33-0.83) group, while the 0.1 LPS group 
displayed a significant reduction only on the sixth week. Locomotor activity also was 
assessed in the open field arena six hours after the LPS or saline injections on week one 
and week six. On week one, the escalating (0.33-0.83) LPS group displayed statistically 
significant hypolocomotion (effect of dose F(3.28)=3.19, p=0.039), but on week six the 
reduction in locomotor activity did not reach statistical significance in comparison with 
the SAL group (effect of dose F(2,23)=1.6, p=0.22, Figure 2(c). 
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Table 1 Two-way repeated measures ANOVA outcomes for weight gain and food intake measures taken each week 
24hrs after either LPS or saline injections for six weeks. 
 8 week old male BALB/cAnNCrl mice were injected with LPS or saline i.p. once a week for 6 weeks. Experimental 
conditions (n=8-10/group) included: 0.1 LPS group injected with 0.1 mg/kg LPS once weekly; Escalating (0.33-0.83) 
LPS group injected with 0.33mg/kg on weeks 1 and 2, 0.53mg/kg on week 3, 0.63 mg/kg on week 4, 0.73 mg/kg on 
week 5 and 0.83 mg/kg on week 6; Single LPS group injected with 0.83 mg/kg on week 1 and saline on weeks 2-6; SAL 
group was injected weekly with 0.9% saline solution.  
Factor Effect size 
(% of total variation) 
F df df Residual p 
Weight gain      
Dose 12.33 24.66 3 30 < 0.0001 
Time 18.36 11.29 5 150 < 0.0001 
Interaction 16.3 3.341 15 150 < 0.0001 
Food intake      
Dose 34.45 24.6 3 13 < 0.0001 
Time 13.92 11.04 5 65 < 0.0001 
Interaction 30.74 8.122 15 65 < 0.0001 
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Figure 2 Short-term sickness behaviour induced by weekly LPS injections.  
8 week old male BALB/cAnNCrl mice were injected with LPS or saline i.p. once a week for 6 weeks. Experimental 
conditions included: 0.1 LPS group injected with 0.1 mg/kg LPS once weekly; Escalating LPS group injected with 
0.33mg/kg on weeks 1 and 2, 0.53mg/kg on week 3, 0.63 mg/kg on week 4, 0.73 mg/kg on week 5 and 0.83 mg/kg 
on week 6; Single LPS group injected with 0.83 mg/kg on week 1 and saline on weeks 2-6; SAL group was injected 
weekly with 0.9% saline solution (a) Weight change measured during first 24hrs after injections each week expressed 
as % change from a baseline measured immediately before the LPS injections. (b) Food intake during first 24hrs after 
weekly injections. (c) locomotor activity on weeks 1 and 6 measured 6hrs after LPS or SAL injections in the open field 
arena; p values derived from Bonferroni multiple comparisons test SAL vs 0.1LPS/Escalating LPS/Single LPS, *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001. Data represents mean±SEM, n=8-10/group. 
 
Repeated exposure modified cytokine response to LPS challenge  
To detect systemic cytokine response to LPS challenge, selected cytokines were 
measured in the peripheral blood collected 2 hours after injection on weeks one and six. 
The time point of blood collection was chosen based on previous studies which showed 
that in mice exposed to LPS blood levels of most cytokines peak within the first two 
hours after exposure and subside at later time points (Biesmans et al., 2013; Browne et 
al., 2012). Animals responded to acute LPS exposure on week one with a profound 
elevation of pro-inflammatory cytokines IL-6 and TNFα. More specifically, IL-6 was 
elevated up to 700-fold compared to control levels depending on the dose of LPS 
injected, while TNFα showed elevations in the range of 20 to 35 fold (see Figure 3 and 
Table 2). Interestingly, other cytokines and inflammatory markers were not elevated at 
this time point, including CRP, IL-5 and IL-2, while others did not reach detection levels 
of the assay used (IL-4, IFNγ, IL-1β). IL-10 showed an elevation on week one, which 
reached significance in the escalating LPS (0.33-0.83) and single LPS groups. GM-CSF also 
significantly increased in response to all doses of LPS on week one. In response to the 
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sixth injection the elevation of IL-6 and particularly TNFα was much reduced compared 
to week one. However, the levels of these pro-inflammatory cytokines were still over 
570 fold (IL-6) and over nine fold (TNFα) increased in the escalating LPS (0.33-0.83) group 
compared to levels observed in the control group (see Figure 3). In contrast, IL-2 was 
over four fold elevated exclusively in response to the escalating LPS (0.33-0.83) group, 
accompanied by an increase in GM-CSF levels in this group, even more robust than on 
week one (20-fold on week one vs 30-fold on week six). Interestingly, CRP was 0.44 fold 
decreased compared to controls in response to the final LPS dose in the escalating LPS 
(0.33-0.83) group.  
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Figure 3 Plasma cytokine profile in response to LPS injections 2hrs after exposure on weeks one and six.  
8 week old male BALB/cAnNCrl mice were injected with LPS or saline i.p. once a week for 6 weeks. Experimental 
conditions included: 0.1 LPS group injected with 0.1 mg/kg LPS once weekly; Escalating LPS group injected with 
0.33mg/kg on weeks 1 and 2, 0.53mg/kg on week 3, 0.63 mg/kg on week 4, 0.73 mg/kg on week 5 and 0.83 mg/kg 
on week 6; Single LPS group injected with 0.83 mg/kg on week 1 and saline on weeks 2-6; SAL group was injected 
weekly with 0.9% saline solution. Data shown as percentage change from control (SAL). P values derived from 
Bonferroni multiple comparisons test SAL vs 0.1LPS/Escalating LPS/Single LPS, *p<0.05, **p<0.01, ***p<0.001 
compared to the SAL control group. Data represents mean±SEM, n=8-10/group.  
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Table 2 One-way ANOVA and post-hoc Bonferroni multiple comparisons of plasma cytokine measures taken 2hrs 
after LPS/SAL exposure on weeks one and six.  
8 week old male BALB/cAnNCrl mice were injected with LPS or saline i.p. once a week for 6 weeks. Experimental 
conditions (n=8-10/group) included: 0.1 LPS group injected with 0.1 mg/kg LPS once weekly; Escalating (0.33-0.83) 
LPS group injected with 0.33mg/kg on weeks 1 and 2, 0.53mg/kg on week 3, 0.63 mg/kg on week 4, 0.73 mg/kg on 
week 5 and 0.83 mg/kg on week 6; Single LPS group injected with 0.83 mg/kg on week 1 and Saline on weeks 2-6; SAL 
group was injected weekly with 0.9% saline solution.  
  One-way ANOVA Bonferroni multiple comparisons  
Cytokine_week 
 
df F p SAL group 
mean, pg/ml 
LPS groups Mean, pg/ml p 
IL-6_w1 
Between Groups 3 
43.40 .000 52.17 
0.1LPS 13517.79 .008 
Within Groups 30 0.33-0.83 LPS 29908.75 .000 
Total 33 Single LPS 40395.00 .000 
IL-6_w6 
Between Groups 3 
23.00 .000 65.13 
0.1LPS 2749.14 .039 
Within Groups 28 0.33-0.83 LPS 5292.88 .000 
Total 31 Single LPS 58.75 1.000 
TNFα_w1 
Between Groups 3 
14.46 .000 14.52 
0.1LPS 125.13 .032 
Within Groups 30 0.33-0.83 LPS 221.65 .000 
Total 33 Single LPS 218.56 .000 
TNFα_w6 
Between Groups 3 
6.95 .001 7.97 
0.1LPS 31.23 1.000 
Within Groups 28 0.33-0.83 LPS 74.45 .002 
Total 31 Single LPS 5.45 1.000 
CRP_w1 
Between Groups 3 
1.47 .242 87759.00 
0.1LPS 112317.50   
Within Groups 30 0.33-0.83 LPS 105770.00   
Total 33 Single LPS 79503.75   
CRP_w6 
Between Groups 3 
4.86 .008 90505.00 
0.1LPS 55210.00 .124 
Within Groups 28 0.33-0.83 LPS 40051.25 .006 
Total 31 Single LPS 71444.29 1.000 
GM-CSF_w1 
Between Groups 3 
27.08 .000 1.77 
0.1LPS 16.79 .024 
Within Groups 30 0.33-0.83 LPS 35.10 .000 
Total 33 Single LPS 40.45 .000 
GM-CSF_w6 
Between Groups 3 
20.11 .000 1.71 
0.1LPS 12.01 1.000 
Within Groups 28 0.33-0.83 LPS 50.60 .000 
Total 31 Single LPS 2.19 1.000 
IL-2_w1 
Between Groups 3 
1.25 .309 15.05 
0.1LPS 18.35   
Within Groups 30 0.33-0.83 LPS 18.31   
Total 33 Single LPS 15.66   
IL-2_w6 
Between Groups 3 
24.97 .000 17.94 
0.1LPS 27.67 1.000 
Within Groups 28 0.33-0.83 LPS 75.31 .000 
Total 31 Single LPS 17.64 1.000 
IL-10_w1 
Between Groups 3 
26.27 .000 8.20 
0.1LPS 81.49 .151 
Within Groups 30 0.33-0.83 LPS 165.93 .000 
Total 33 Single LPS 272.39 .000 
IL-5_w1 
Between Groups 3 
1.26 .306 27.34 
0.1LPS 31.77   
Within Groups 30 0.33-0.83 LPS 32.43   
Total 33 Single LPS 30.00   
IL-5_w6 
Between Groups 3 
1.34 .283 28.08 
0.1LPS 30.18   
Within Groups 28 0.33-0.83 LPS 32.98   
Total 31 Single LPS 29.59   
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Hippocampal microglia was not affected by LPS exposure 
The estimation of the number of Iba1 positive cells in neurogenic granular zone of the 
dentate gyrus, as well as in the whole hippocampus showed that the number of 
microglia was not altered in the long term (seven days later) by LPS injections (Effect of 
treatment F (3,20) = 0.45, p = 0.72, see Fig.4(a)). The level of microglial activation was 
assessed by the density of CD68-positive puncta in the tissue. According to this analysis, 
LPS exposure did not have a long term effect on microglial activation in DG, CA1 and CA3 
areas of the hippocampus (see Figure 4(b)). Additionally, we investigated whether 
systemic LPS exposure affected the level of plasma corticosterone. For this purpose, 
blood was collected via cardiac puncture seven days after the last LPS injections. High 
individual variability was observed in the systemic corticosterone levels and as a 
consequence no statistical differences were detected amongst mean group levels (see 
Figure 4(c)). 
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Figure 4 Hippocampal microglia cell number and activation marker expression in mice exposed to chronic LPS/SAL 
injections. 
8 week old male BALB/cAnNCrl mice were injected with LPS or saline i.p. once a week for 6 weeks. Experimental 
conditions (n=8-10/group) included: 0.1 LPS group injected with 0.1 mg/kg LPS once weekly; Escalating (0.33-0.83) 
LPS group injected with 0.33mg/kg on weeks 1 and 2, 0.53mg/kg on week 3, 0.63 mg/kg on week 4, 0.73 mg/kg on 
week 5 and 0.83 mg/kg on week 6; Single LPS group injected with 0.83 mg/kg on week 1 and saline on weeks 2-6; SAL 
group was injected weekly with 0.9% saline solution. (a) Number of Iba1 positive cells in the dentate gyrus of the 
hippocampus was unaffected by LPS exposure, ns (b) CD68 positive surface area, detected in images taken from 
different regions of the hippocampus, also was unchanged by LPS exposure (DG – dentate gyrus, CA1 and CA3 – Cornu 
Ammonis areas), ns (c) Corticosterone levels detected in the cardiac blood 7 days after last LPS injections. Data 
represents mean±SEM. 
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LPS injections affected the number of postmitotic immature neurons in the 
hippocampal dentate gyrus.  
In the tissue collected seven days after the last injections, the level of proliferating Ki67 
positive cells was not altered (see Figure 5(a)).  Also, a one-way ANOVA showed that the 
number of DCX positive immature neurons was not affected by LPS injections (F (3, 26) 
= 1.862, p = 0.161). However the number of “EF” type postmitotic neuroblasts was 
significantly affected by treatment conditions (F (3,26)=15.46, p<0.0001). Post-hoc 
Bonferroni multiple comparisons showed that weekly injections of 0.1 mg/kg LPS 
increased the number of postmitotic DCX positive neurons and the same effect was 
induced by a single 0.83 mg/kg LPS injection in single LPS group. In contrast, the number 
of postmitotic neuroblasts in the escalating LPS (0.33-0.83) group was reduced 
compared to the saline-injected control (see Figure 5(b)).  
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Figure 5 Adult hippocampal neurogenesis and corticosterone levels in the LPS/SAL-exposed animals 
8 week old male BALB/cAnNCrl mice were injected with LPS or saline i.p. once a week for 6 weeks. Experimental 
conditions (n=8-10/group) included: 0.1 LPS group injected with 0.1 mg/kg LPS once weekly; Escalating (0.33-0.83) 
LPS group injected with 0.33mg/kg on weeks 1 and 2, 0.53mg/kg on week 3, 0.63 mg/kg on week 4, 0.73 mg/kg on 
week 5 and 0.83 mg/kg on week 6; Single LPS group injected with 0.83 mg/kg on week 1 and saline on weeks 2-6; SAL 
group was injected weekly with 0.9% saline solution. (a) Number of proliferating Ki67 positive cells in the dentate 
gyrus of the hippocampus was unchanged by LPS injections, ns (b) Representative micrographs of DG show DCX+ cells 
with their dendritic trees (in dark-brown), scale bar = 500 µm (c) Total number of DCX+ cells was not significantly 
changed by LPS injections; DCX+ cells were then classified according to their dendritic morphology: AB – no or short 
dendrites, CD – medium length dendrites without branching; EF – long branching dendrites reaching the molecular 
layer. Data represents mean±SEM; P values derived from Bonferroni multiple comparisons test SAL vs 
0.1LPS/Escalating LPS/Single LPS, *p<0.05, **p<0.01 
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Discussion 
In this study we investigated the change in sickness behaviour and plasma cytokine 
levels in response to repeated and escalating dose LPS injections. Our data showed that 
systemic exposure to escalating doses of LPS administered once a week for six weeks 
repeatedly induced core aspects of sickness behaviour, such as reduced food intake and 
weight loss. In contrast, the effect induced by the repeated 0.1 mg/kg LPS dose was 
present only intermittently. However, hypolocomotion detected in the open field test 
in the escalating LPS (0.33-0.83) group on week one was reduced on week six, which 
could be reflecting a degree of developing LPS tolerance. It is also likely that the 
locomotor activity data was affected by a relatively late timing of assessment (6 hours 
post injections) and a repeated exposure to the open field arena.  
Assessment of peripheral cytokine levels in response to LPS showed that chronic 
escalating dose injections resulted in a cytokine profile distinct from acute response, 
while single and low dose repeated LPS injections did not induce any long-lasting 
changes in the blood cytokine levels. The escalating dose induced profile includes a 
lower magnitude of elevation of proinflammatory cytokines IL-6 and TNFα, reduction of 
CRP and contrasting elevation of IL-2 and GM-CSF. These changes partly point towards 
a developing tolerance to LPS, but are contradicted by an absence of the anti-
inflammatory IL-10 elevation on week six typically accompanying endotoxin tolerance 
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(Biswas and Lopez-Collazo, 2009). The surprising absence of CRP elevation on week 1 is 
likely to be linked to the early timing of blood collection, as CRP levels are known to peak 
at 18 hours post LPS challenge (Szalai et al., 2000). Thus week 6 reduction potentially 
reflects chronic suppression of CRP in-between LPS stimulations. Noteworthy, TNFα 
levels detected on week 6 were similar to that previously reported in a chronic (2 weeks) 
LPS administration paradigm which included LPS injections i.p. at a dose of 0.05mg/kg 
(Elgarf et al., 2014). 
Elevation of IL-2 and GM-CSF by escalating dose exposure is of particular interest. It has 
been reported that depressed patients have elevated plasma levels of soluble IL-2 
receptor (Maes et al., 1995), and more recently elevation of IL-2 levels in the blood has 
been reported in chronic obstructive pulmonary disease patients with comorbid 
depression (Rybka et al., 2016). Pro-inflammatory GM-CSF (Shi et al., 2006) has been 
previously shown to be elevated in the blood by 3 consecutive but not single injections 
of 3mg/kg LPS in mice (Erickson and Banks, 2011). The increase of GM-CSF and IL-2 
cytokines in response to chronic injections may reflect an alternative state of immune 
system activation, distinct from the conventional response to a single LPS exposure and 
from the previously described endotoxin tolerance. However it is likely to have some 
features of immunosuppression as reflected by a reduction in CRP level. Many repeated 
LPS studies limit their serological analysis to a single cytokine (Elgarf et al., 2014; Wang 
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et al., 2011), therefore it is difficult to compare current results to most of the previously 
published data. 
Interestingly, single 0.83 mg/kg dose did not induce any long-lasting changes in the 
cytokine levels, albeit this dose induced long-lasting depression-like behaviour in a 
previous study (Painsipp et al., 2011). It is important to note that plasma cytokine levels 
might not be representative of the cytokine content in the brain. Indeed, several studies 
have shown that after repeated LPS injections levels of peripheral blood pro-
inflammatory cytokines might return to control levels whilst the level of cytokine 
expression in the  brain remains high (Chen et al., 2005; Fischer et al., 2015; Norden et 
al., 2016).  
Due to the suggested role of adult hippocampal neurogenesis in depression 
neurobiology and in the mechanism of antidepressant action, we asked if systemic 
chronic LPS exposure would alter the rate of AHN. LPS did not affect cell proliferation in 
the DG in accordance with previously published studies (Belarbi et al., 2012; Ormerod 
et al., 2013), and did not change the level of neuronal differentiation reflected by the 
DCX-positive cell density. Importantly most previous studies which showed effect of LPS 
on AHN utilised higher doses such as 1 mg/kg or more and looked at an earlier time point 
of post LPS exposure assessment (Graciarena et al., 2013; Monje, 2003; Ormerod et al., 
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2013). However, we found that escalating dose LPS reduced the number of postmitotic 
“EF”-type DCX positive neurons. It has been previously shown that LPS can disrupt 
morphological maturation of DCX positive cells (Valero et al., 2014). The effect of 
escalating dose injections on the postmitotic morphology replicates the effect which 
chronic mild stress, an animal model of depression, exerts on dendritic branching of 
DCX-positive hippocampal cells (Qiao et al., 2016; Sousa et al., 2000; Vega-Rivera et al., 
2016; Vyas et al., 2002). Importantly, this effect is thought to underlie the reduction of 
hippocampal volume described in neuroimaging studies of depressed patients 
(Lorenzetti et al., 2009). As dendritic morphology is a form of neural plasticity, this effect 
could also be involved in a cognitive decline frequently observed in clinical depression 
(Femenía et al., 2012). Interestingly, a single 0.83 mg/kg LPS dose, as well as repeated 
0.1 mg/kg LPS doses caused an opposite effect, an increase in the number of post-
mitotic “EF” type neuroblasts, which could be part of a compensatory increase in 
neurogenesis previously described 7 days after LPS exposure (Valero et al., 2014). 
We next speculated if activation of microglia might be affecting the adult hippocampal 
neurogenesis following LPS exposure. Microglia are known to have the ability to 
modulate neurogenesis during an inflammatory insult (Belarbi and Rosi, 2013; Ekdahl, 
2012), potentially through a release of pro-inflammatory cytokines, which have been 
shown to exert a detrimental effect on neural stem cells proliferation and differentiation 
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(Koo and Duman, 2008; Zunszain et al., 2012). It has been commonly described that 
systemic LPS exposure induces microglial activation in the hippocampus (Ho et al., 2015; 
Noh et al., 2014). However, in our study LPS exposure did not have a long-lasting effect 
on the hippocampal microglia as reflected by Iba-1 and CD68 markers density. This 
negative result could indicate the insufficiency of the escalating dose LPS exposure to 
induce microglial activation. It is also likely that a relatively late timepoint of assessment 
compared to previous studies (Borges et al., 2012) and an absence of morphological 
assessment which could more accurately reflect activation state of microglial cells 
contributed to this result.   
Another notable finding in the biological parameters is the absence of an increase in 
blood corticosterone levels previously reported in response to  LPS administration 
(Browne et al., 2012). It has been shown that corticosterone levels return to baseline 
within the first 24 hours post LPS exposure (Clark et al., 2015; Silverman et al., 2013) , a 
time period within which most studies looking at single or repeated LPS effects assess 
its levels (Kubera et al., 2013; Sulakhiya et al., 2016). Thus timing of blood collection (7 
days post last LPS administration) could explain the lack of the effect in our study, which 
in turn suggests that once weekly injections might not be sufficient to maintain 
continuous hypercortisolism in mice. The lack of chronic corticosterone elevation could 
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also account for the absence of decline in the hippocampal neurogenesis, as this has 
been attributed to the glucocorticoid receptor activation (Anacker et al., 2011). 
Conclusions 
In this study we showed that weekly injections with escalating but not constant dose of 
LPS increasing from 0.33 to 0.83 mg/kg induce a weekly sickness behaviour response, 
with partial development of LPS tolerance reflected by a lack of hypolocomotion some 
suppression of the inflammatory pathways as reflected by blood CRP levels and a 
weakening of pro-inflammatory cytokine secretion. However, it also comprises an 
increase in factors capable of stimulating leukocyte proliferation, including an increase 
in plasma IL-2, previously implicated in depression, not seen in repeated or single dose 
exposed group. Additionally, assessment of AHN shows that only exposure to a weekly 
escalating doses in the range of 0.33-0.83 mg/kg of LPS decelerates dendritic maturation 
of new neurons in the hippocampal dentate gyrus. This effect is in line with previous 
observations of the effect of depression-modelling interventions on AHN in animals, and 
is relevant for hippocampal volume changes and cognitive decline observed in 
depressed patients. These findings suggest that repeated LPS injections modify sickness 
behaviour and immune response in mice, however weekly LPS injections with escalating 
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doses in the range of 0.33-0.83 mg/kg could be a suitable model to induce some 
neurobiological aspects of the chronic inflammatory state observed in mood disorders. 
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